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Abstract 
Obesity plays a key role in the pathophysiology of type 2 diabetes (T2DM), and weight loss is a major objective, 
although difficult to achieve with medical treatments. Bariatric surgery has proven its efficacy in obtaining 
marked and sustained weight loss, and is also associated with a significant improvement in glucose control and 
even diabetes remission. Roux-en-Y gastric bypass appears to be more effective in diabetic patients than the 
restrictive gastroplasty procedure. This may be explained not only by greater weight reduction, but also by 
specific hormonal changes. Indeed, increased levels of glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) may lead to improved β-cell function and insulin secretion as well as reduced 
insulin resistance associated with weight loss. The presence of T2DM in obese individuals is a further argument 
to propose bariatric surgery, and even more so when diabetes is difficult to manage by medical means and other 
weight-related complications are present. Bariatric surgery is associated with a better cardiovascular prognosis 
and reduced mortality, even though acute and long-term complications may occur. The observation that surgical 
rerouting of nutrients triggers changes in the release of incretin hormones that, in turn, ameliorate the diabetic 
state in the absence of weight loss has led to the recent development of innovative surgical procedures. Thus, 
bariatric surgery may be said to be progressing towards so-called 'metabolic surgery', which merits further 
evaluation in patients with T2DM within a multidisciplinary approach that involves both surgeons and 
endocrinologists. 
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Résumé 
Chirurgie bariatrique chez les patients atteints de diabète de type 2: bénéfices, risques, indications et 
perspectives 
L'obésité joue un rôle-clé dans la physiopathologie du diabète de type 2 (DT2) et l'obtention d'une perte de poids 
est un objectif majeur, bien que difficile à atteindre avec les moyens médicaux. La chirurgie bariatrique a apporté 
la preuve de son efficacité pour induire un amaigrissement marqué et soutenu, qui s'accompagne d'une 
amélioration du contrôle glycémique et assez souvent d'une remission du diabète. La dérivation gastrique avec 
l'anse de Roux-en-Y apparaît être plus efficace chez les patients diabétiques que la simple technique restrictive 
qu'est la gastroplastie calibrée. Ceci peut s'expliquer non seulement par une perte pondérale supérieure, mais 
aussi par des modifications hormonales spécifiques. En effet, une augmentation des concentrations de GLP-1 
(glucagon-like peptide-1) et de GIP (glucose-dependent insulinotropic polypeptide) avec la dérivation permet 
d'améliorer la fonction de la cellule β et la réponse insulinosécrétoire, en plus de la diminution de 
l'insulinorésistance consécutive à l'amaigrissement. La présence d'un DT2 chez un sujet obèse est un argument 
supplémentaire pour proposer une chirurgie bariatrique, d'autant plus que le diabète est difficile à gérer avec les 
moyens médicaux et qu'il existe d'autres complications liées à l'excès de poids. La chirurgie bariatrique est 
associée à un meilleur pronostic cardiovasculaire et à une diminution de la mortalité, même si cette chirurgie 
peut également occasionner des complications à court et à long terme. L'observation que la dérivation gastro-
intestinale des aliments stimule la sécrétion des hormones incrétines, susceptibles d'améliorer le diabète en 
l'absence de perte de poids, a conduit récemment au développement de nouvelles procédures chirurgicales. Ainsi, 
la chirurgie bariatrique pourrait évoluer vers une chirurgie métabolique. Cette dernière mérite d'être mieux 
évaluée chez les patients DT2, dans une approche multidisciplinaire impliquant une collaboration étroite entre 
chirurgiens et endocrinologues. 
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1.  Introduction 
Obesity is a major independent risk factor for the development of type 2 diabetes mellitus (T2DM) and is also 
associated with the rapidly increasing prevalence of diabetes [1, 2]. The majority of patients (> 80%) diagnosed 
with T2DM are overweight [body mass index (BMI) > 25 kg/m2], and roughly 50% are obese (BMI > 30 kg/m2) 
and almost 10% are morbidly obese (BMI > 40 kg/m2). This twin epidemic of obesity and diabetes has serious 
consequences with increased cardiovascular morbidity and premature mortality. However, studies have shown 
that weight loss, even when modest, can reduce the incidence of T2DM in patients with impaired glucose 
tolerance and improve blood glucose control (and other cardiovascular risk factors) in patients with T2DM, 
while marked weight loss can even lead to resolution/remission of diabetes [2]. 
Lifestyle interventional programmes including diet therapy, behavioural modification, exercise regimens and 
pharmacotherapy are widely used in various combinations [3, 4]. Unfortunately, clinically significant weight loss 
is uncommon and mostly transient, particularly in patients with severe obesity and with T2DM, for whom 
sustained weight reduction is even more difficult to achieve. 
Bariatric surgery is a rapidly evolving branch of surgical science [5-7]. The aim is to induce major weight loss in 
those whose obesity places them at high risk of severe health problems, including T2DM [7-9]. In an attempt to 
balance the risks of surgery against the benefits of weight loss, bariatric operations are currently performed only 
in the morbidly obese (BMI > 40 kg/m2) and in those with a BMI > 35 kg/m2 and co-morbidities such as T2DM 
[10]. In the mid-1990s, Pories et al. [11] proposed the provocative theory that T2DM might be a surgical disease, 
as bariatric surgery proved to be the most effective approach for treating and even resolving this type of diabetes 
[12]. Over the past 10 years, bariatric surgery has gained an increasing place in the management of obese 
patients with T2DM [13-16]. Moreover, the suggestion that the foregut plays an important role in the 
pathophysiology of T2DM opens up new possibilities for a surgical approach in patients with T2DM, even in 
absence of severe obesity, as well as a nominal shift from 'bariatric'to 'metabolic'surgery [17, 18]. 
The present review focuses mainly on the benefit- risk profile of bariatric surgery in the management of obese 
patients with T2DM, but also includes a discussion of the mechanisms of action of various surgical procedures, 
the factors influencing prognosis and validated indications in clinical practice. In addition, new perspectives for 
metabolic surgery in non-obese patients with T2DM are also briefly discussed. 
2.   Surgical techniques 
A number of surgical approaches to induce weight loss have been developed, and several are also currently used 
in the management of obese patients with T2DM [5, 6]. In general, these procedures can be classified as: solely 
restrictive [laparoscopic adjustable gastric banding (LAGB) and its variant, vertical banded gastroplasty (VGB)] 
[19]; mostly restrictive [Roux-en-Y gastric bypass (RYGB)] [20]; and mostly malabsorptive [biliopancreatic 
diversion with duodenal switch (BPDS)] [21]. In the first group, the mechanism essentially hinges upon 
generating effective satiety signals with only small amounts of ingested food [19]. In the second group, a degree 
of gastric restriction is coupled with bypass of the duodenum and upper jejunum, a procedure that may also 
result in important hormonal changes for glycaemic control (see below) [20]. In the third group of procedures, 
only the final 50 cm of the total length of the bowel is available for ingested food and biliopancreatic juices to 
mix, leading to consistent nutrient malabsorption [21]. 
These techniques have all been proven effective in the management of obese patients with or without T2DM. 
However, as these surgical procedures are different, their efficacy-to-safety balance may also differ. Techniques 
with a component of malabsorption generally lead to more pronounced and more sustained weight loss compared 
with solely restrictive procedures [22]. As for tolerability and safety, patients treated with LAGB had lower 
short-term morbidity than those treated with RYGB, but repeat-operation rates are higher among patients who 
undergo LAGB. However, according to a recent Cochrane review, although certain procedures result in greater 
weight loss, well-validated comparative data are nevertheless limited. The evidence for safety is even less clear. 
Because of the limited evidence and poor quality of trials, the reviewers concluded that caution is required when 
interpreting comparative safety and effectiveness [23]. 
Innovative bariatric surgical procedures continue to be under investigation. The gastric sleeve, or sleeve 
gastrectomy, is certainly among the more advanced and already in routine use in some centres [24,25]. The 
procedure results in a narrow gastric tube through excision of most of the stomach. The operation does more than 
just limit intake, but also removes most—or perhaps all—of the ghrelin-producing cells in the gastric mucosa. In 
addition, two new procedures—the duodenojejunal bypass stomach-sparing operation [26] and ileal transposition 
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[27-29]—have been tested in attempts to induce remission of diabetes without weight loss in lean or only 
modestly overweight patients with T2DM. However, both are still in the early stages of human trials (see 
Perspectives below). Nevertheless, there is little doubt that the mechanism of action on glucose metabolism 
differs depending on the type of bariatric surgery [30]. 
3.  Mechanisms of metabolic improvement 
Bariatric surgery is a highly effective means of inducing diabetes remission in very obese patients with T2DM 
[31]. Diabetes remission results from improvements in both insulin resistance and β-cell dysfunction. Better 
insulin action on glucose metabolism relieves secretory pressure on the β-cell, resulting in reduced insulin output 
[32, 33]. However, significant improvements in dynamic β-cell responses may also play a role. This may be the 
result of reduced glucotoxicity and/or specific incretin effects favouring β-cell function. By rank order of 
increasing efficacy in glucose control, the most common surgical procedures go from the solely restrictive to the 
mostly restrictive and to the mostly malabsorptive, thus paralleling their weight-reducing effects. The 
mechanisms responsible for glycaemic improvement and resolution/ remission of diabetes after bariatric surgery 
also depend on the type of surgical procedure used. 
Calorie restriction and weight loss are the dominant mechanisms of improved glucose metabolism when solely 
restrictive procedures are applied [8, 19]. The former appears to account for the early post-surgical recovery of 
insulin sensitivity and secretory dynamics, while the latter is the final determinant of outcome once weight and 
caloric balance have stabilized [32, 33]. In general, when analyzing the effect of solely restrictive procedures, the 
sustained improvement of glucose control is directly proportional to the final amount of weight loss. However, 
even with RYGB, the percentage of weight lost is a predictive factor of diabetes remission [34]. 
When food transit is surgically altered, changes in the pattern of gastrointestinal hormone release may support 
early adaptation of β-cell function, but this is unlikely to make a major contribution to insulin action. Weight-
independent antidiabetic effects with RYGB are evident from the rapid resolution of T2DM (before weight loss 
occurs), the greater improvement of glucose homoeostasis after RYGB than after equivalent weight loss by other 
means and the occasional development of very-late-onset pancreatic β-cell hyperfunctioning. Several 
mechanisms probably mediate the direct antidiabetic impact of RYGB, including: enhanced nutrient stimulation 
of L-cell peptides [for example, glucagon-like peptide-1 (GLP-1)] from the lower intestine ('hindgut 
hypothesis'); the intriguing, but as yet uncharacterized, phenomena related to exclusion of the upper intestine 
from contact with ingested nutrients ('foregut hypothesis'); compromised ghrelin secretion; and most likely other 
effects that have yet to be identified [30, 35, 36]. Indeed, a role for glucagon or gut-derived glucagonotropic 
signalling as putative diabetogenic signals from the foregut has been recently proposed [37]. Research designed 
to prioritize these mechanisms and identify potential additional mechanisms promises to help in the 
optimalization of surgical design (see Perspectives below) and may also reveal novel pharmaceutical targets for 
antidiabetes drug treatments [36]. 
4.   Clinical benefits 
The dataset of a recent systematic review and meta-analysis included 621 studies with 888 treatment arms and 
135,246 patients; of these studies, 103 treatment arms, involving 3188 patients, reported resolution of diabetes—
that is, resolution of the clinical and laboratory manifestations of T2DM [38]. In addition, 19 studies with 43 
treatment arms and 11,175 patients reported both weight loss and diabetes resolution in 4,070 diabetic patients. 
At baseline, the patients'mean age was 40.2 years, BMI was 47.9 kg/m2, 80% were female and 10.5% had 
undergone previous bariatric procedures. Meta-analysis showed an overall loss of 38.5 kg or 56% of excess body 
weight. Also, 78% of the diabetic patients enjoyed complete resolution of their disease, while diabetes was 
improved or resolved in nearly 87%. Weight loss and diabetes resolution were greatest for patients undergoing 
BPDS, followed by RYGB, and was lowest with LAGB. Insulin levels declined significantly postoperatively, as 
did glycated haemoglobin (HbA1c) and fasting glucose values. Weight and diabetes parameters showed little 
differences within 2 years, or after 2 or more years, of follow-up. The conclusion was that the clinical and 
laboratory manifestations of T2DM were resolved or improved in the vast majority of patients after bariatric 
surgery, and these responses are more pronounced with procedures that led to a greater percentage of excess 
weight loss maintained for 2 or more years. 
Besides the effect on glucose control, bariatric surgery also leads to significant improvement of cardiovascular 
risk factors, especially those linked with the metabolic syndrome, including inflammation markers [39]. The 
prospective Swedish Obese Subjects (SOS) study confirmed that bariatric surgery significantly improves 
glucose, lipid and blood pressure control in surgically compared with medically treated obese individuals [40]. 
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Recently, the 10.9-year follow-up of the SOS study reported a significant 30% risk reduction in overall mortality 
in 2,010 obese patients (7.4% with T2DM) who had undergone bariatric surgery [41]. Likewise, in a 
retrospective US cohort of 7,925 surgical patients mostly treated with RYGB, mortality from any cause was 
significantly 40% lower than in 7,925 non-surgical obese patients [42]. However, mortality data for a specific 
diabetic cohort are scanty. In an early retrospective analysis of two groups of obese diabetic patients, the 
mortality rate (including perioperative deaths) in the control medical group was 28% after 6.2 years compared 
with only 9% in the RYGB surgical group after 9 years. For every year of follow-up, patients in the control 
group had a 4.5% risk of dying vs 1.0% for those in the surgical group. The improvement in mortality with 
surgery was primarily due to a decrease in the number of cardiovascular deaths [43]. 
Recently, a systematic review concluded that bariatric surgery appears to be a clinically and cost-effective 
intervention for moderate-to-severely obese people compared with non-surgical interventions [44]. However, 
uncertainties persist and further research is required. In particular, new research needs to investigate the 
resolution and/or development of T2DM and, more important, the duration of T2DM remission, so that the 
potential benefits of early intervention may be better assessed. 
5.  Prognostic factors 
Studies of postoperative outcomes for bariatric surgery have provided information on the predictors of success. 
Indeed, the surgeon's and institution's experience, and patients'behaviour after surgery, are key determinants of 
its success or failure in all obese subjects, including those with T2DM [45]. 
Rates of total diabetes remission and glycaemic improvement essentially depend on the type of surgical 
intervention, as already stated. Although physiological (hormonal) mechanisms probably contribute to RYGB 
outcomes, early rapid weight loss and the percentage of excess weight lost were also significant factors 
associated with diabetes remission in a multivariate analysis [34]. In addition, in that study, the preoperative 
insulin dose was another predictor, suggesting that the severity of diabetes plays a crucial role. This may be 
indexed by disease duration, HbA1c level, intensity of treatment and presence of complications [46]. Diabetes 
duration is generally related to a progressive reduction in β-cell function and/or mass, which may hinder 
remission of diabetes even after marked weight loss if surgery is performed too late. HbA1c is a classical marker 
not only of glucose control, but also, indirectly, of diabetes severity. The higher the initial HbA1c level, the lower 
the chances of diabetes remission after bariatric surgery. Similarly, the intensity of treatment also plays a major 
part. Insulin-treated patients are less prone to complete remission of diabetes compared with patients taking oral 
treatment, and recovery of adequate glucose control despite stopping insulin therapy would be an alternative—
and perhaps more realistic— efficacy criterion in such a diabetic subgroup. Among patients using oral therapy, 
the rate of complete diabetes remission is higher in those treated with monotherapy compared with those already 
receiving the maximum oral combined treatment. The presence of diabetic complications (such as nephropathy 
and retinopathy) should probably be considered an indirect marker of longstanding, poorly controlled diabetes 
rather than a direct contributor to surgical treatment failure. 
Other factors, such as adiposity topography, T2DM family history, interaction with previous antidiabetic 
therapies and evidence of autoimmunity (late-onset type 1 diabetes) have not been specifically analyzed and 
merit further evaluation. 
6.   Risks 
The risk and type of complications related to bariatric surgery among diabetic patients are not much different 
from those in a non-diabetic population, although some (such as infections) are more prevalent in diabetics. 
Surprisingly, bariatric surgery is remarkably safe, especially given the large body size of patients, and the 
frequency and seriousness of co-morbidities. Nevertheless, the operative mortality rate is low: the 30-day 
mortality rates reported in a recent meta-analysis were LAGB = 0.1%, VBG = 0.1%, RYGB = 0.5% and BPDS = 
1.1% [47]. However, death may also occur after discharge from hospital, possibly due to pulmonary embolism 
and arrhythmias [6]. 
Surgical complications are either acute or long term [6]. Acute complications occur in 5-10% of patients—
depending on the procedure, and the patients'risk, age and condition—and mirror those following other 
abdominal operations, including haemorrhage, obstruction, anastomotic leaks, infection, arrhythmias and 
pulmonary emboli. Long-term complications are miscellaneous and mostly include neuropathies due to 
nutritional deficiencies, internal hernias, anastomotic stenoses and emotional disorders. Although nutritional 
deficits can be avoided with daily multivitamin and mineral supplements, compliance with this recommendation 
Published in : Diabetes & Metabolism (2009), vol. 35 
Status : Postprint (Author’s version) 
 
is not universal, and dramatic complications due to severe deficiencies may occur, albeit rarely. In general, 
however, the complications do not differ in diabetic, compared with non-diabetic, patients [48]. 
The risk of hypoglycaemia sometimes reported in non-diabetic individuals late after RYGB (attributed to the 
development of neisidioblastosis) does not appear to affect diabetic patients. However, calorie restriction, weight 
loss and incretin-related mechanisms may dramatically improve glucose control and lead to early hypoglycaemia 
if no appropriate reduction in glucose-lowering therapies is made soon after surgery. Ideally, this should be 
performed as a preventative approach rather than waiting for hypoglycaemic episodes to occur before 
considering adjustment of any antidiabetic treatment [7]. Similarly, antihypertensive therapy, commonly used in 
obese patients with T2DM, should be frequently adjusted after bariatric surgery to avoid hypotension leading to 
orthostatic dizziness. 
7.   Indications 
The first indications and contraindications for bariatric surgery were established in 1991 by the US National 
Institutes of Health (NIH) Consensus Conference on surgery for obesity [10]. In 2004, the American Society for 
Bariatric Surgery (ASBS; now the American Society for Metabolic and Bariatric Surgery, or ASMBS), updated 
that statement with a follow-up Consensus Conference [49]. In practical terms, most physicians, surgeons and 
carers consider patients eligible for bariatric surgery if their BMI is at least 40 kg/m2, or at least 35 kg/m2 if 
accompanied by co-morbidities such as T2DM, hypertension, severe arthritis (limiting daily function) and 
cardiopulmonary failure. In the past, the age limit was 18-65 years, but recent data show that teenagers and 
patients over 65 can benefit from surgery with little or no increases in risk. Other inclusion criteria include the 
patient's ability to understand the surgery and its consequences, and to comply with long-term follow-up, and the 
patient's agreement to maintain vitamin and mineral supplementation, and to report problems promptly to 
specialists familiar with the complications of bariatric surgery. Similar recommendations were made in the 2007 
Interdisciplinary European guidelines for surgery for those with severe (morbid) obesity [50]. 
Thus, T2DM as a complication of obesity is a further argument to propose bariatric surgery even when BMI is 
35-40 kg/m2, as stated in the official recommendations [10, 49, 50]. From a practical point of view, it is 
reasonable to consider as major indications either those patients whose T2DM is difficult to manage or poorly 
controlled mainly because of the presence of severe obesity, or those who, in addition to diabetes, have several 
risk factors directly related to excess weight that may markedly worsen their overall prognosis (such as 
hypertension, dyslipidaemia and sleep apnoea). However, the choice of procedure is not yet based on sound data 
[23], although many surgeons currently favour either RYGB or the duodenal switch over LAGB in patients with 
T2DM for reasons discussed above [7, 15, 16, 22]. 
8.  Perspectives 
Certain types of bariatric surgical procedures have proved not only to be effective for treating obesity, but also 
appear to be associated with endocrine changes that, independent of weight loss, give rise to remission of T2DM 
[37, 51]. Observations in animals and in humans suggest that changes in the gut hormonal milieu after bypass of 
the distal stomach, duodenum and proximal jejunum can influence T2DM, despite the absence of significant 
weight loss [17, 51]. As a result, the use of bypass bariatric surgery and experimental gastrointestinal 
manipulations to treat T2DM is increasing among less obese patients (BMI < 35 kg/m2 or even < 30 kg/ m2). 
While BMI currently represents a significant indication for bariatric surgery (see Indications above), evidence 
shows that, so far, no clear cut-off BMI score accurately predicts successful surgical outcomes. Furthermore, 
BMI appears to have limited value in defining the risk profile in T2DM patients. For this reason, the current 
BMI-based criteria for bariatric surgery may not be an adequate indication for such patients [17]. 
There is also increasing evidence that bariatric operations may exert intrinsic antidiabetic actions beyond weight 
loss. Malabsorptive operations currently offer the best chances of revealing weight-independent mechanisms of 
diabetes resolution, but other smart manipulations of food passage may open up entirely new avenues of 
treatment. At present, it is speculated that surgical rerouting of nutrients triggers changes in the release of 
gastrointestine-derived hormones that, in turn, ameliorate the diabetic state. The hindgut hypothesis states that 
surgical rerouting of nutrients to the distal part of the small intestine results in increased secretion, and 
concomitant glucose-lowering effects, of GLP-1, whereas the foregut hypothesis emphasizes that surgical bypass 
of the foregut prevents the release of hitherto unidentified nutrient-induced diabetogenic signals (? 
glucagon/glucagonotropic signalling) in susceptible individuals [37]. Recent animal investigations using 
duodenojejunal bypass, a stomach-preserving experimental model of RYGB, have shown that diabetes control is 
not a mere collateral effect of the treatment of obesity, but directly results from exclusion of the duodenum and 
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proximal jejunum from the flow of nutrients. A recent report has described lean T2DM patients who experienced 
marked improvement of their diabetes with duodenojejunal exclusion surgery that was independent of changes in 
BMI, fat distribution and body composition [26]. Such a surgical approach was superior to standard care in 
achieving better glycaemic control, along with reduction or even interruption in insulin requirements. Also, as an 
alternative approach, ileal transposition may result in significant endocrine changes in the gut, particularly by 
promoting secretion of GLP-1, an ileal-produced hormone with a well-known role in T2DM [27]. Promising 
results with ileal interposition (the so-called 'neuroendocrine break') combined with sleeve gastrectomy were 
recently reported in a small series of patients with T2DM and no obesity [28, 29]. Adequate glycaemic control 
was obtained in > 90% of the patients and several hormonal changes were also observed, especially a marked 
increase in GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). 
Large randomized clinical trials against the best medical care should be prioritized to define the role of bariatric 
surgery in the management of diabetes. Experiments involving less obese or non-obese diabetic patients, or 
minimizing weight loss, may provide further evidence in favour of so-called metabolic surgery [18]. However, 
difficult as they may be to carry out, controlled clinical studies using state-of-the-art methodology (including 
randomization if possible) are necessary to establish the value of metabolic surgery. It would also be of interest 
to assess the efficacy/safety of bariatric/metabolic surgery in special populations presenting with diabetes, such 
as pregnant women, adolescents and individuals who are at least 65 years old [48]. 
9.   Conclusion 
Numerous studies demonstrate that bariatric surgery for obesity can lead to substantial and sustained weight loss. 
In addition, patients with T2DM have experienced remission of hyperglycaemia or a reduced need for 
medication. These are partly explained by weight loss, but also by specific hormonal changes, especially after 
bypass procedures that alter the passage of food in the gut. This may explain why RYGB appears to be superior 
to LAGB in obese patients with T2DM. Surgical intervention for patients with more recent diabetes onset may 
see higher rates of resolution than patients with longer T2DM duration because of less-advanced disease and a 
better insulin secretory reserve. In addition to better glucose control, dyslipidaemia, hypertension and other risk 
factors improve more markedly in patients treated by surgery compared with those receiving the optimal medical 
treatment. Such pleiotropic effects may offer special benefits to those with T2DM, who are also known to 
present with high cardiovascular risks. Observational studies and the prospective SOS trial suggest that long-
term survival is favourable for obese (diabetic) patients following bariatric surgery. This suggests that early 
surgical intervention in cases of T2DM associated with other weight-related complications may be clinically 
appropriate in patients for whom operative risks are acceptable, with no contraindications. Finally, new surgical 
procedures are currently undergoing evaluation and may be proposed in future for management of T2DM, even 
in the absence of severe obesity. Thus, the old paradigm of bariatric surgery may progress towards a new 
paradigm of 'metabolic obesity'. Recognizing the need to work as a team across disciplines—in particular, 
endocrinologists and surgeons—is the first step towards addressing the issues and opportunities that surgery has 
to offer diabetes care and research. 
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